Amarin 3Q 2026: Revenue $39.6M, Product Revenue $36.9M — 10-Q Summary

What happened

Amarin reported third-quarter 2026 revenue of $39.6 million, down 20% from $49.7 million a year earlier. Product revenue fell 24% to $36.9 million due to lower net selling prices from customer mix.

Confirmed

Global impact / market context

Falling revenue and a lower gross margin, which means the profit left after product costs, leave less cash to fund U.S. marketing and partner support. Investors may question how long current spending can be sustained without revenue recovery.

Analyst inference

U.S. branded prescriptions rose 12% over nine months, yet lower customer-mix pricing cut U.S. product revenue. That means volume growth is not converting into sales, while European product revenue declined and partners led VAZKEPA commercialization across 59 countries.

Analyst inference

What to watch

1. Amarin said it would focus on maintaining U.S. market leadership and supporting partners' commercialization, pricing, reimbursement and licensing efforts, which signals management priorities for coming quarters. Confirmed
2. Watch whether lower customer-mix pricing persists or reverses, since cheaper net selling prices, which means the average amount received per sale after discounts, drove most of the product revenue decline. Proposed
3. If gross margin stays near 37% and revenue keeps falling, cash available could tighten, potentially limiting clinical support and forcing trade-offs in capital spending on U.S. promotion. Analyst inference

Evidence

• Original source link unavailable